Efficacy of an alcohol-focused intervention for improving adherence to antiretroviral therapy (ART) and HIV treatment outcomes – a randomised controlled trial protocol

BMC Infectious Diseases

Paul A Shuper⁷  Jürgen Rehm²  Judith A Hahn³  Gita Ramjee⁸  Katherine Sorsdahl⁹  Samuel OM Manda⁴  Connie T Kekwaletswe^1,10  Bronwyn J Myers⁵  Neo K Morojele⁶  Charles DH Parry¹ 

[1] Department of Psychiatry, University of Stellenbosch, Cape Town, South Africa;Technische Universität Dresden, Klinische Psychologie & Psychotherapie, Dresden, Germany;Department of Medicine, University of California San Francisco, San Francisco, CA, USA;Biostatistics Unit, Medical Research Council, Pretoria, South Africa;Department of Psychiatry and Mental Health, University of Cape Town, Cape Town 7700, South Africa;School of Public Health, University of the Witwatersrand, Johannesburg, South Africa;Center for Health, Intervention, and Prevention, University of Connecticut, Storrs, CT, USA;Department of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom;Alan J Flisher Centre for Public Mental Health, Department of Psychiatry, University of Cape Town Cape Town, South Africa;Alcohol, Tobacco and Other Drug Research Unit, Medical Research Council, Pretoria, South Africa

关键词: Brief intervention;    Randomised controlled trial;    South Africa;    Alcohol;    HIV/AIDS;   

Others  :  1125562
DOI  :  10.1186/1471-2334-14-500

 received in 2014-08-22, accepted in 2014-09-08,  发布年份 2014

【 摘 要 】

Background

Little research has examined whether alcohol reduction interventions improve antiretroviral therapy (ART) adherence and HIV treatment outcomes. This study assesses the efficacy of an intervention for reducing alcohol use among HIV patients on ART who are hazardous/harmful drinkers. Specific aims include adapting a blended Motivational Interviewing (MI) and Problem Solving Therapy (PST) intervention for use with HIV patients; evaluating the efficacy of the intervention for reducing alcohol consumption; and assessing counsellors’ and participants’ perceptions of the intervention.

Methods/Design

A randomised controlled trial will evaluate the intervention among ART patients in public hospital-based HIV clinics in Tshwane, South Africa. We will recruit patients who are HIV-positive, on ART for at least 3 months, and classified as harmful/hazardous drinkers using the AUDIT-3. Eligible patients will be randomly assigned to one of three conditions. Patients in the experimental group will receive the MI-PST intervention to reduce harmful/hazardous alcohol use. Patients in the equal-attention wellness intervention group will receive an intervention focused on addressing health risk behaviours. Patients in the control condition will receive treatment as usual. Participants will complete an interviewer-administered questionnaire at baseline and 3, 6 and 12 months post-randomisation to assess alcohol consumption, ART adherence, physical and mental health. We will also collect biological specimens to test for recent alcohol consumption, CD4 counts and HIV RNA viral loads. The primary outcome will be reduction in the volume of alcohol consumed. Secondary outcomes include reduction in harmful/hazardous use of alcohol, reduction in biological markers of drinking, increase in adherence rates, reductions in viral loads, and increases in CD4 T-cell counts. A process evaluation will ascertain counsellors’ and participants’ perceptions of the acceptability and effectiveness of the interventions.

Discussion

We have obtained ethical approval and approval from the study sites and regional and provincial health departments. The study has implications for clinicians, researchers and policy makers as it will provide efficacy data on how to reduce harmful/hazardous alcohol consumption among HIV patients and will shed light on whether reducing alcohol consumption impacts on HIV treatment adherence and other outcomes.

Trial registration

Pan African Clinical Trials Register Number: PACTR201405000815100.

【 授权许可】

   
2014 Parry et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Hahn JA, Woolf-King SE, Muyindike W: Adding fuel to the fire: alcohol’s effect on the HIV epidemic in sub-Saharan Africa. Cur HIV/AIDS Rep 2011, 8(3):172-180.
• [2]Hahn JA, Samet JH: Alcohol and HIV disease progression: weighing the evidence. Cur HIV/AIDS Rep 2010, 7(4):226-233.
• [3]Pandrea I, Happel KI, Amedee AM, Bagby GJ, Nelson S: Alcohol’s role in HIV transmission and disease progression. Alcohol Res Health 2010, 33(3):203-218.
• [4]Shuper PA, Neuman M, Kanteres F, Baliunas D, Joharchi N, Rehm J: Causal considerations on alcohol and HIV/AIDS-a systematic review. Alcohol Alcohol 2010, 45:159-166.
• [5]WHO: Global Status Report on Alcohol and Health 20l4. Geneva, Switzerland: Author; 2014.
• [6]HIV CAUSAL Collaboration: The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010, 24:123-137.
• [7]García de Olalla P, Knobel H, Carmona A, Guelar A, López-Colomés JL, Caylà JA: Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002, 30:105-110.
• [8]Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, Montaner JS: Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS 2008, 22:2371-2380.
• [9]Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, Montaner JS: The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 2009, 2009(50):529-536.
• [10]Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, Chaisson RE, Maartens G: Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 2006, 43:78-84.
• [11]Parsons JT, Rosof E: The temporal relationship between alcohol consumption and HIV-medication adherence: A multilevel model of direct and moderating effects. Health Psychol 2008, 27:628-637.
• [12]Kalichman SC, Amaral CM, White D, Swetsze C, Pope H, Kalichman MO, Chauncey C, Eaton L: Prevalence and clinical implications of interactive toxicity beliefs regarding mixing alcohol and antiretroviral therapies among people living with HIV/AIDS. AIDS Patient Care STDs 2009, 23:449-454.
• [13]Kalichman SC, Amaral CM, White D, Swetsze C, Kalichman MO, Cherry C, Eaton L: Alcohol and adherence to antiretroviral medications: interactive toxicity beliefs among people living with HIV. J Assoc Nurses AIDS Care 2012, 23:511-520.
• [14]Kalichman SC, Grebler T, Amaral CM, McNerey M, White D, Kalichman MO, Chauncey C, Eaton L: Intentional non-adherence to medications among HIV positive alcohol drinkers: prospective study of interactive toxicity beliefs. Int J Gen Med 2013, 28:399-405.
• [15]Lyimo RA, de Bruin M, van den Boogaard J, Hospers HJ, van der Ven A, Mushi D: Determinants of antiretroviral therapy adherence in northern Tanzania: a comprehensive picture from the patient perspective. BMC Public Health 2012, 12:716. BioMed Central Full Text
• [16]Hendershot CS, Stoner SA, Pantalone DW, Simoni JM: Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr 2009, 52:180-201.
• [17]Braithwaite RS, McGinnis KA, Conigliaro J, Maisto SA, Crystal S, Day N, Cook RL, Gordon A, Bridges MW, Seiler JFS, Justice AC: A temporal and dose–response association between alcohol consumption and medication adherence among veterans in care. Alcohol Clin Exp Res 2005, 29:1190-1197.
• [18]Braithwaite RS, Conigliaro J, Roberts MS, Shechter S, Schaefer A, McGinnis K, Rodriguez MC, Rabeneck L, Bryank K, Justice AC: Estimating the impact of alcohol consumption on survival for HIV + individuals. AIDS Care 2007, 19:459-466.
• [19]Bagasra O, Kajdacsy-Balla A, Lischner HW, Pomerantz RJ: Alcohol intake increases human immunodeficiency virus type 1 replication in human peripheral blood mononuclear cells. J Infect Dis 1993, 167:789-797.
• [20]Bagasra O, Bachman SE, Jew L, Tawadros R, Cater J, Boden G, Ryan I, Pomerantz RJ: Increased HIV type-1 replication in human peripheral blood mononuclear cells induced by ethanol: potential immunopathogenic mechanisms. J Infect Dis 1996, 173:550-558.
• [21]Chander G, Lau B, Moore RD: Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr 2006, 43:411-417.
• [22]Liu X, Zha J, Nishitani J, Chen H, Zack JA: HIV-1 infection in peripheral blood lymphocytes (PBLs) exposed to alcohol. Virology 2003, 307:37-44.
• [23]Wu AW, Revicki DA, Jacobson D, Malitz FE: Evidence for reliability, validity and usefulness of the medical outcomes study HIV health survey (MOS-HIV). Qual Life Res 1997, 6:481-493.
• [24]Baum MK, Rafie C, Lai S, Sales S, Page JB, Campa A: Alcohol use accelerates HIV disease progression. AIDS Res Hum Retroviruses 2010, 26:511-518.
• [25]Pol S, Artru P, Thépot V, Berthelot P, Nalpas B: Improvement in the CD4 count after alcohol withdrawal in HIV positive alcoholic patients. AIDS 1996, 10:1293-1294.
• [26]Samet JH, Cheng DM, Libman H, Nunes DP, Alperen JK, Saitz R: Alcohol consumption and HIV disease progression. J Acquir Immune Defic Syndr 2007, 46:194-199.
• [27]Naar-King S, Wright K, Parsons JT, Frey M, Templin T, Lam P, Murphy D: Healthy choices: motivational enhancement therapy for health risk behaviors in HIV-positive youth. AIDS Educ Prev 2006, 18:1-11.
• [28]Naar-King S, Lam P, Wang B, Wright K, Parsons JT, Frey MA: Brief report: maintenance of effects of motivational enhancement therapy to improve risk behaviors and HIV-related health in a randomized controlled trial of youth living with HIV. J Pediatr Psychol 2008, 33:441-445.
• [29]Parsons JT, Golub SA, Rosof E, Holder C: Motivational interviewing and cognitive-behavioral intervention to improve HIV medication adherence among hazardous drinkers: a randomized controlled trial. J Acquir Immune Defic Syndr 2007, 46:443-450.
• [30]Samet JH, Horton NJ, Meli S, Dukes K, Tripps T, Sullivan L, Freedberg KA: A randomized controlled trial to enhance antiretroviral therapy adherence in patients with a history of alcohol problems. Antivir Ther 2005, 10:83-93.
• [31]Kaner EF, Beyer F, Dickonson HO, Pienaar E, Campbell F, Schlesinger C, Heather N, Saunders JB, Burnand B: Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev 2007., 18(2) CD004148
• [32]Miller WR, Wilbourne PL: Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders. Addict 2002, 97:265-277.
• [33]Pilowsky DJ, Wu LT: Screening for alcohol and drug use disorders among adults in primary care: a review. Subst Abuse Rehabil 2012, 3:25-34.
• [34]Berglund M, Thelander S, Jonsson E: Treating Alcohol and Drug Abuse. An Evidenced Based Review. New York: John Wiley; 2003.
• [35]Martin G, Rehm J: The effectiveness of psychosocial modalities in the treatment of alcohol problems in adults: a review of the evidence. Can J Psychiatry 2012, 57:350-358.
• [36]Smedslund G, Berg RC, Hammerstrom KT, Steiro A, Leiknes KA, Dahl HM, Karlsen K: Motivational interviewing for substance abuse. Cochrane Database Syst Rev 2011., 5CD008063
• [37]Magill M, Ray LA: Cognitive-behavioral treatment with adult alcohol and illicit drug users: a met;a-analysis of randomized controlled trials. J Stud Alcohol Drugs 2009, 70:516-527.
• [38]Malouff JM, Thorsteinsson EB, Schutte NS: The efficacy of problem solving therapy in reducing mental and physical health problems: a meta-analysis. Clin Psychol Rev 2007, 27:46-57.
• [39]Rosen D, Morse JQ, Reynolds CF: Adapting problem solving therapy for depressed older adults in methadone maintenance treatment. J Subst Abuse Treat 2011, 40:132-141.
• [40]Sorsdahl K, Stein DJ, Cararri H, Myers B: Problem solving deficits among people who use alcohol and other drugs in South Africa. Addict Behav 2014, 39:122-126.
• [41]Sorsdahl K, Myers B, Ward CL, Matzopoulos R, Mtukushe B, Nicol A, Cuijpers P, Stein DJ: Adapting a blended motivational interviewing and problem-solving intervention to address risky substance use amongst South Africans. Psychother Res 2014. doi:10.1080/10503307.2014.897770
• [42]Kekwaletswe CT, Morojele NK: Alcohol use, antiretroviral therapy adherence, and preferences regarding an alcohol-focused adherence intervention in patients with human immunodeficiency virus. Patient Prefer Adherence 2014, 8:401-413.
• [43]Hasin DS, Aharonovich E, O’Leary A, Greenstein E, Pavlicova M, Arunajadai S, Waxman R, Wainberg M, Helzer J, Johnson B: Reducing heavy drinking in HIV primary care: a randomised trial of brief intervention, with and without technological enhancement. Addict 2013, 108:1230-1240.
• [44]Morojele NK, Kekwaletswe C, Nkosi S: Associations between alcohol use, other psychosocial factors, structural factors and antiretroviral therapy (ART) adherence among South African ART recipients. AIDS Behav 2013, 18:519-524.
• [45]Sorsdahl K, Myers B, Ward C, Matzopoulos R, Mtukushe B, Nicol A, Cuijpers P, Stein DJ: Adapting a problem solving therapy intervention to address substance use: results of a feasibility study. International Inj Control Saf Promot 2014. doi:10.1080/10503307.2014.897770
• [46]Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG: AUDIT. The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Care (2nd ed.). Geneva: World Health Organisation; 2011.
• [47]D’Zurilla TJ, Nezu AM, Maydeu-Olivares A: Manual for the Social Problem-Solving Inventory-revised (SPSI-R). North Tonawanda, NY: Multi-Health Systems; 2002.
• [48]Van’t Hof E, Stein DJ, Marks I, Tomlinson M, Cuijpers P: The effectiveness of problem solving therapy in deprived South African communities: results from a pilot study. BMC Psychiatry 2011, 11:e156. BioMed Central Full Text
• [49]Rollnick S, Heather N, Gold R, Hall W: Development of a short ‘readiness to change’ questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict 1992, 87:743-754.
• [50]Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl BDD, Wu AW: Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. Patient care committee & adherence working group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000, 12:255-266.
• [51]Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR: Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials 2004, 5:74-79.
• [52]Mannheimer SB, Mukherjee R, Hirschhorn LR, Dougherty J, Celano SA, Ciccarone D, Graham KK, Mantell JE, Mundy LM, Eldred L, Botsko M, Finkelstein R: The CASE adherence index: a novel method for measuring adherence to antiretroviral therapy. AIDS Care 2006, 18:853-861.
• [53]Feldman BJ, Fredericksen RJ, Crane PK, Safren SA, Mugavero MJ, Willig JH, Simoni JM, Wilson IB, Saag MS, Kitahata MM, Crane HM: Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. AIDS Behav 2013, 17:307-318.
• [54]Lu M, Safren SA, Skolnik PR, Rogers WH, Coady W, Hardy H, Wilson IB: Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav 2008, 12:86-94.
• [55]Ware J, Kosinski M, Dewey J, Gandek B: How to Score and Interpret Single-Item Health Status Measures: A Manual for Users of the SF-8 Health Survey. Boston: Quality Metric Incorporated; 2001.
• [56]Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SL, Walters EE, Zaslavsky AM: Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med 2002, 32:959-976.
• [57]Berman AH, Bergman H, Palmstierna T, Schlyter F: Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample. Eur Addict Res 2005, 11:22-31.
• [58]Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO: The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. BrJ Addict 1991, 86:1119-1127.
• [59]Hahn JA, Dobkin LM, Mayanja B, Emenyonu NI, Kigozi IM, Shiboski S, Bangsberg DR, Gnann H, Weinmann W, Wurst FM: Phosphatidylethanol (PEth) as a biomarker of alcohol consumption in HIV-positive patients in Sub-Saharan Africa. Alcohol Clin Exp Res 2012, 36:854-862.
• [60]Viel G, Boscolo-Berto R, Cecchetto G, Fais P, Nalesso A, Ferrara SD: Phosphatidylethanol in blood as a marker of chronic alcohol use: a systematic review and meta-analysis. Int J Mol Sci 2012, 13:14788-14812.
• [61]Kagee A, Remien RH, Berkman A, Hoffman S, Campos L, Swartz L: Structural barriers to ART adherence in Southern Africa: challenges and potential ways forward. Glob Public Health 2011, 6:83-97.
• [62]Sherbourne CD, Stewart AL: The MOS social support survey. Soc Sci Med 1991, 32:705-714.
• [63]Johnson MO, Neilands TB, Dilworth S, Morin SF, Remien RH, Chesney MA: The role of self-efficacy in HIV treatment adherence: validation of the HIV treatment adherence self-efficacy scale (HIV-ASES). J Behav Med 2007, 30:359-370.
• [64]Karnofsky DA, Burchenal JH: The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In Evaluation of Chemotherapeutic Agents. Edited by MacLeod CM. New York: Columbia University Press; 1949:191-205.
• [65]Mor V, Laliberte L, Morris JN, Wiemann M: The Karnofsky performance status scale: an examination of its reliability and validity in a research setting. Cancer 1984, 53:2002-2007.
• [66]Sacktor NC, Wong M, Nakasujja N, Skolasky RL, Selnes OA, Musisi S, Robertson K, McArthur J, Allan R, Katabira E: The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005, 19:1367-1374.
• [67]QSR International: NVivo qualitative data analysis software (Version 10). Australia: Doncaster, Victoria; 2012. QSR International Pty Ltd
• [68]Matovu JK: Preventing HIV transmission in married and cohabiting HIV-discordant couples in sub-Saharan Africa through combination prevention. Curr HIV Res 2010, 8(6):430-440.
• [69]Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan MO, Lutalo T, Gray RH: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000, 342:921-929.